205 related articles for article (PubMed ID: 22156453)
41. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
Chong TW; Horwitz LD; Moore JW; Sowter HM; Harris AL
Cancer Res; 2002 Dec; 62(23):6924-7. PubMed ID: 12460908
[TBL] [Abstract][Full Text] [Related]
42. Natural polyphenols against neurodegenerative disorders: potentials and pitfalls.
Ebrahimi A; Schluesener H
Ageing Res Rev; 2012 Apr; 11(2):329-45. PubMed ID: 22336470
[TBL] [Abstract][Full Text] [Related]
43. Neuroprotection from complement-mediated inflammatory damage.
Kulkarni AP; Kellaway LA; Lahiri DK; Kotwal GJ
Ann N Y Acad Sci; 2004 Dec; 1035():147-64. PubMed ID: 15681806
[TBL] [Abstract][Full Text] [Related]
44. The cross-talk between NF-kappaB and HIF-1: further evidence for a significant liaison.
Görlach A; Bonello S
Biochem J; 2008 Jun; 412(3):e17-9. PubMed ID: 18498249
[TBL] [Abstract][Full Text] [Related]
45. Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism.
Pollak Y; Mechlovich D; Amit T; Bar-Am O; Manov I; Mandel SA; Weinreb O; Meyron-Holtz EG; Iancu TC; Youdim MB
J Neural Transm (Vienna); 2013 Jan; 120(1):37-48. PubMed ID: 22446839
[TBL] [Abstract][Full Text] [Related]
46. Hinokitiol activates the hypoxia-inducible factor (HIF) pathway through inhibition of HIF hydroxylases.
Lee MJ; Kim JW; Yang EG
Biochem Biophys Res Commun; 2010 May; 396(2):370-5. PubMed ID: 20416277
[TBL] [Abstract][Full Text] [Related]
47. Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons.
Zheng H; Youdim MB; Weiner LM; Fridkin M
Biochem Pharmacol; 2005 Nov; 70(11):1642-52. PubMed ID: 16226724
[TBL] [Abstract][Full Text] [Related]
48. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection.
Stone TW; Forrest CM; Darlington LG
FEBS J; 2012 Apr; 279(8):1386-97. PubMed ID: 22248239
[TBL] [Abstract][Full Text] [Related]
49. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases.
Mandel S; Youdim MB
Free Radic Biol Med; 2004 Aug; 37(3):304-17. PubMed ID: 15223064
[TBL] [Abstract][Full Text] [Related]
50. Advances in iron chelation: an update.
Heli H; Mirtorabi S; Karimian K
Expert Opin Ther Pat; 2011 Jun; 21(6):819-56. PubMed ID: 21449664
[TBL] [Abstract][Full Text] [Related]
51. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice.
Kupershmidt L; Amit T; Bar-Am O; Youdim MB; Weinreb O
Mech Ageing Dev; 2012 May; 133(5):267-74. PubMed ID: 22426424
[TBL] [Abstract][Full Text] [Related]
52. The role of iron in brain ageing and neurodegenerative disorders.
Ward RJ; Zucca FA; Duyn JH; Crichton RR; Zecca L
Lancet Neurol; 2014 Oct; 13(10):1045-60. PubMed ID: 25231526
[TBL] [Abstract][Full Text] [Related]
53. Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus.
Mechlovich D; Amit T; Bar-Am O; Weinreb O; Youdim MB
Br J Pharmacol; 2014 Dec; 171(24):5636-49. PubMed ID: 25073425
[TBL] [Abstract][Full Text] [Related]
54. Iron chelation in the treatment of neurodegenerative diseases.
Dusek P; Schneider SA; Aaseth J
J Trace Elem Med Biol; 2016 Dec; 38():81-92. PubMed ID: 27033472
[TBL] [Abstract][Full Text] [Related]
55. Iron chelating strategies in systemic metal overload, neurodegeneration and cancer.
Gumienna-Kontecka E; Pyrkosz-Bulska M; Szebesczyk A; Ostrowska M
Curr Med Chem; 2014; 21(33):3741-67. PubMed ID: 25005181
[TBL] [Abstract][Full Text] [Related]
56. Role of HIF-1 in iron regulation: potential therapeutic strategy for neurodegenerative disorders.
Lee DW; Andersen JK
Curr Mol Med; 2006 Dec; 6(8):883-93. PubMed ID: 17168739
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic applications of chelating drugs in iron metabolic disorders of the brain and retina.
Shahandeh A; Bui BV; Finkelstein DI; Nguyen CTO
J Neurosci Res; 2020 Oct; 98(10):1889-1904. PubMed ID: 32643793
[TBL] [Abstract][Full Text] [Related]
58. Brain iron accumulation in aging and neurodegenerative disorders.
Hagemeier J; Geurts JJ; Zivadinov R
Expert Rev Neurother; 2012 Dec; 12(12):1467-80. PubMed ID: 23237353
[TBL] [Abstract][Full Text] [Related]
59. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases.
Van der Schyf CJ; Gal S; Geldenhuys WJ; Youdim MB
Expert Opin Investig Drugs; 2006 Aug; 15(8):873-86. PubMed ID: 16859391
[TBL] [Abstract][Full Text] [Related]
60. Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy.
Merelli A; Czornyj L; Lazarowski A
Curr Pharm Des; 2013; 19(38):6791-801. PubMed ID: 23530506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
